同行影响对医生使用乳腺癌短程外照射放疗的作用
该研究基于Medicare乳腺癌患者队列,按患者共享关系构建医生同行组,采用纵向混合效应逻辑回归分析2011-2012年同行组短程EBRT使用率与2013-2014年患者接受短程EBRT的关联。结果显示同行组显著影响辅助治疗中中度大分割EBRT的使用,但不影响骨转移短程姑息EBRT的使用。
要点
- 同行组辅助治疗中度大分割EBRT使用率越高,患者T2接受该治疗的可能性越大。
- 同行组对骨转移短程姑息EBRT的使用无显著影响。
- 医生同行组影响短程EBRT在辅助治疗而非姑息治疗中的传播。
核心结论
- 医生同行组显著影响乳腺癌辅助治疗中短程EBRT的使用,但不影响骨转移姑息治疗中短程EBRT的使用。
研究设计与样本
- 基于Medicare乳腺癌受益人的队列研究,按患者共享关系构建医生同行组,采用纵向混合效应逻辑回归分析。
主要发现
- T2期间共17,248例患者接受辅助治疗(32.3%为中度大分割),来自1202个医生同行组的3235名医生。
- 与T1无中度大分割辅助EBRT使用的同行组相比,T1使用率21%-46%的同行组调整OR=2.03(95%CI 1.62-2.54),47%-100%的同行组调整OR=2.61(95%CI 2.04-3.35)。
- T1同行组使用与T2骨转移短程姑息EBRT接受无显著关系。
关键数值与推荐
- T1同行组中度大分割辅助EBRT使用率21%-46%时调整OR=2.03(95%CI 1.62-2.54)。
- T1同行组中度大分割辅助EBRT使用率47%-100%时调整OR=2.61(95%CI 2.04-3.35)。
临床怎么用
- 可利用医生同行网络促进辅助治疗中短程EBRT的推广,但姑息治疗中短程EBRT的推广可能需要其他策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Social contagion among physicians may affect the dissemination of innovative and high-value cancer care. We applied social contagion theory to investigate the role of physician peer influence on the use of short courses of external beam radiation therapy (EBRT) for patients with breast cancer. METHODS AND MATERIALS: Using a cohort of Medicare beneficiaries with breast cancer, we constructed physician peer groups based on patient-sharing relationships. Outcomes were a patient's receipt of (1) moderately hypofractionated adjuvant EBRT after breast-conserving surgery and (2) short-course palliative EBRT for bone metastases. Using a longitudinal design, we used mixed-effects logistic regression to examine the association between physician peer group rate of short-course EBRT in 2011 to 2012 (T1) and patients' receipt of short-course EBRT in 2013 to 2014 (T2). RESULTS: During T2, a total of 17,248 patients received adjuvant therapy (32.3% moderately hypofractionated) from 3235 physicians in 1202 physician peer groups. Compared with patients treated within peer groups in which no moderately hypofractionated adjuvant EBRT was used in T1, patients treated by a physician in a peer group with higher T1 use of moderately hypofractionated adjuvant EBRT were more likely to receive moderately hypofractionated adjuvant EBRT in T2 (adjusted odds ratio = 2.03; 95% confidence interval, 1.62-2.54, vs adjusted odds ratio = 2.61; 95% confidence interval, 2.04-3.35, for peer groups where 21%-46% and 47%-100% of radiation oncologists used moderately hypofractionated adjuvant EBRT in T1, respectively, compared with peer groups with no use of moderately hypofractionated adjuvant EBRT). In contrast, there was no significant relationship between T1 peer group use and T2 receipt of short-course palliative EBRT for bone metastases. CONCLUSIONS: Physician peer groups significantly influenced use of short-course EBRT in adjuvant therapy but not in palliative therapy for patients with breast cancer.
引用
- Yu JB, Pollack CE, Herrin J, et al. Peer Influence on Physician Use of Shorter Course External Beam Radiation Therapy for Patients with Breast Cancer. Pract Radiat Oncol. 2019. PMID: 31785370. doi:10.1016/j.prro.2019.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。